5wrx: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "5wrx" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
The | ==VG13P structure in LPS== | ||
<StructureSection load='5wrx' size='340' side='right' caption='[[5wrx]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[5wrx]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5WRX OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5WRX FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5wrx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5wrx OCA], [http://pdbe.org/5wrx PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5wrx RCSB], [http://www.ebi.ac.uk/pdbsum/5wrx PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5wrx ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
In this study, we report an interaction study of a 13-residue analogue peptide VG13P (VARGWGRKCPLFG), derived from a designed VG16KRKP peptide (VARGWKRKCPLFGKGG), with a Lys6Gly mutation and removal of the last three residues Lys14-Gly15-Gly16, in lipopolysaccharide (LPS), a major component of the outer membrane of Gram-negative bacteria and responsible for sepsis or septic shock. VG13P displays an enhanced anti-endotoxin property as evident from significant reduction in LPS-induced TNF-alpha gene expression levels in a monocytic cell line, while it retains almost unchanged antimicrobial activity as its parent VG16KRKP against Gram-negative bacterial as well as fungal pathogens. In addition, in vitro LPS binding properties of VG13P in comparison to its parent VG16KRKP also remained unhindered, suggesting that the flexible C-terminal end of VG16KRKP may not play a major role in its observed antibacterial and LPS binding properties. An NMR-resolved solution structure of VG13P in LPS reveals two consecutive beta-turns: one at the N-terminus, followed by another at the central region, closely resembling a rocking chair. The crucial Lys6Gly mutation along with C-terminal truncation from VG16KRKP reorients the hydrophobic hub in VG13P in a unique way so as to fold the N-terminal end back on itself, forming a turn and allowing Val1 and Ala2 to interact with Leu11 and Phe12 to bring the hydrophobic residues closer together to form a more compact hub compared to its parent. The hub is further strengthened via CH-pi interaction between Gly4 and Phe12. This accounts for its improved anti-endotoxin activity as well as to its uninterrupted antimicrobial activity. | |||
Structural and Dynamic Insights into a Glycine-Mediated Short Analogue of a Designed Peptide in Lipopolysaccharide Micelles: Correlation Between Compact Structure and Anti-Endotoxin Activity.,Datta A, Jaiswal N, Ilyas H, Debnath S, Biswas K, Kumar D, Bhunia A Biochemistry. 2017 Mar 7;56(9):1348-1362. doi: 10.1021/acs.biochem.6b01229. Epub , 2017 Feb 21. PMID:28168875<ref>PMID:28168875</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 5wrx" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Bhunia, A]] | |||
[[Category: Datta, A]] | |||
[[Category: Antimicrobial peptide]] | |||
[[Category: Antimicrobial protein]] | |||
[[Category: De novo protein]] | |||
[[Category: Endotoxin neutralisation]] | |||
[[Category: Turn and loop-like structure]] | |||
Revision as of 12:54, 10 May 2017
VG13P structure in LPS
| ||||||||||||